Boston Scientific to Acquire Veniti


August 8, 2018—Boston Scientific Corporation announced it has signed an agreement to acquire Veniti, Inc., a privately held company based in Fremont, California, that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The completion of this transaction is imminent, subject to customary closing conditions.

According to Boston Scientific, the self-expanding, nitinol Vici stent system was developed specifically for the challenges of the venous anatomy. The device is designed to withstand compression and maintain patency and flexibility over the course of a patient's life expectancy. The Vici stent system is an investigational device and is not available for sale in the United States.

In June 2018, Veniti submitted a premarket approval application to the FDA supported by results from the recently completed VIRTUS pivotal study. The Vici stent system received European CE Mark approval in 2013.

Boston Scientific has been an investor in Veniti since 2016 and currently owns 25% of the company. The transaction price for the remaining stake consists of $108 million upfront cash, as well as up to $52 million in payments contingent on FDA approval of the Vici stent system, advised the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.